



June 28, 2004

**Encision Inc. Announces Resignation of President and CEO; Appointment of Chairman**

BOULDER, Colo., June 28, 2004 -- /PRNewswire-FirstCall/ -- Encision Inc. (Amex: ECI), a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, announced today that James A. Bowman has resigned as President and CEO of the company. Mr. Bowman will also step down from his post on Encision's board of directors.

Vern D. Kornelsen, a current director of Encision, said, "We are very grateful to Jim for his hard work and dedication to the company over the past four years, and wish him well in his future endeavors." Mr. Kornelsen said that the company's board of directors has initiated a search for a new CEO.

The Company also announced that Encision's board of directors appointed Roger C. Odell as Chairman of the Board. Mr. Odell is a co-founder and Vice President, Business Development of the Company and has been a Director since its inception. From 1976 until 1991, Mr. Odell was employed at Valleylab in a variety of increasingly responsible engineering capacities, primarily involving electrosurgical products. Mr. Odell holds an associate of applied science degree in electrical engineering from Alfred State University.

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward- looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Marcia McHaffie

Controller

Encision Inc.

303-444-2600 x101